To validate these findings, we performed ex vivo analyses of tumor specimens from both TNBC patients and syngeneic murine models by quantitative reverse-transcription PCR (qRT-PCR), immunoblotting, immunohistochemical staining, and multiplexed immunofluorescence co-localization assays, and confirmed differential expression of the PCD-related prognostic genes and the presence of CEBPB+ CAFs. Here, CEBPB is linked to neoplasm.